With this in mind, CAR-Ts engineered to produce CCL19 and IL-7 (CCL19-IL-7 CAR-Ts) can act in a similar fashion as fibroblastic reticular cells in terms of T cell and DC recruitment to the desired tumor sites to help amplify tumoricidal effects (150). The gene discussed is CCL19; the disease is neoplasm.